Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Study: Nearly 6 in 10 Women Projected to Have Cardiovascular Disease by 2050
A new American Heart Association study released Feb. 25 projects that 60% of U.S. women will develop cardiovascular disease by 2050. The analysis shows rising rates of heart disease, heart failure, atrial fibrillation and stroke, driven by higher prevalence of hypertension, obesity and diabetes. It also predicts that roughly one‑third of girls aged 2‑19 could be obese by 2050. These trends signal a looming public‑health crisis for women.
Feds Extend a Telehealth Rule that Could Help Save More People From Opioid Overdoses
The DEA and HHS have extended the pandemic‑era telehealth rule that lets providers prescribe buprenorphine for opioid use disorder without an in‑person visit, now allowing up to six months of remote treatment. Effective Jan. 1, the rule also eliminates record‑keeping requirements...
Hawaii District Court Upholds State 340B Contract Pharmacy Law
A Hawaii district court has upheld the state’s 340B contract‑pharmacy law, ruling that it is not preempted by federal regulations. The decision aligns with recent rulings in Minnesota and Louisiana that support state authority over 340B contract arrangements. The law...
Avoiding the 'Tech Talk Trap' In Healthcare, AI and Health IT Communications
Terry Rubin, co‑founder of The Professional Communicators, will address the “Tech Talk Trap” at HIMSS 2026, highlighting how jargon, information overload, and rapid delivery can alienate healthcare audiences. He explains that experts often lose message control when they prioritize technical...
PFO Closure After Thromboembolism Linked to Strong 20-Year Outcomes
A new 20‑year follow‑up of 130 patients who received transcatheter patent foramen ovale (PFO) closure after a paradoxical embolism shows sustained safety and efficacy. The cohort, with a mean age of 46, experienced a recurrent stroke rate of 0.04 per...
Iron Nanoparticle Eliminates Tuberculosis in Mice and May Pave the Way for New Treatments
Brazilian researchers have shown that an iron‑based compound, ferroin, encapsulated in lipid nanoparticles, completely eradicated Mycobacterium tuberculosis from mouse lungs after a 30‑day course. The formulation, LNP@FEP, stabilizes the drug, enhances the activity of existing antibiotics, and targets bacterial cell‑wall synthesis....
Zimmer Biomet Says Its SynTuition Algorithm Enhances Diagnostic Certainty
Zimmer Biomet announced that its machine‑learning tool SynTuition dramatically improves diagnostic certainty for periprosthetic joint infection (PJI). In a study of 274 real‑world cases, the algorithm matched expert diagnoses 96% of the time, outpacing a pooled physician group that achieved...
Soft-Robotic Glove Uses 37 Actuators to Cut Hand Swelling by up to 25%
Cornell researchers unveiled EdemaFlex, a soft‑robotic glove equipped with 37 shape‑memory‑alloy actuators that apply sequential pressure across all five fingers and the palm. In a small home‑use study of seven edema patients, a single 30‑minute session reduced hand volume by...
Housecall Providers to Affiliate With Chapters Health System
Oregon‑based Housecall Providers has signed a definitive agreement to affiliate with Chapters Health System, extending the nonprofit’s footprint in the Pacific Northwest. The transaction is slated to close in late spring or early summer 2026, subject to regulatory clearance. The...
Withdrawn | Non-Malignant Hematological, Neurological, and Other Disorder Indications Accelerated Approvals
The FDA has removed several accelerated approvals for non‑malignant hematological, neurological, and other disorder indications after post‑marketing requirements were withdrawn. These withdrawn indications are not reflected in official listings until a Federal Register notice or label update is issued. The...
Dotinurad (FYU-981)
Dotinurad (FYU‑981), marketed as Urece®, is a URAT1 inhibitor approved for gout and hyperuricemia in Japan and China. The drug was chemically refined from the older uricosuric benzbromarone to retain potency while eliminating rare hepatotoxic events. Crystalys Therapeutics is now...
Ongoing | Non-Malignant Hematological, Neurological, and Other Disorder Indications Accelerated Approvals
The FDA’s ongoing accelerated‑approval list details 30+ drugs for non‑malignant hematologic, neurologic and other rare disorders that remain contingent on post‑marketing requirements (PMRs). Each entry cites the indication, approval date, specific confirmatory trial design, and a projected completion date ranging...
Accelerated Approval Program
The FDA’s Accelerated Approval Program permits earlier market entry for drugs treating serious conditions by relying on surrogate endpoints that predict clinical benefit. Companies must later complete confirmatory trials; positive results convert the approval to traditional status, while negative outcomes...
Drive Strategic Growth with Smarter Workforce Planning
U.S. hospitals are pairing enterprise resource planning (ERP) systems with AI‑powered human capital management (HCM) platforms to tighten workforce planning as clinical services expand. Leaders at Johns Hopkins, Henry Ford and Rush describe multi‑year integrations that promise real‑time staffing visibility,...
Psychedelic Stocks Overhyped as Nominee Warns Caution
Psychedelic tape still trades on vibes > policy. Surgeon General nominee Casey Means says she “would not recommend” psilocybin to the American people today. Yes, she nods to “exciting work” in PTSD and veterans. But that is a far cry from...
A Review of Efforts to Develop Stem Cell Therapies for Neurodegenerative Conditions
Stem cell therapies for neurodegenerative diseases span unregulated, low‑evidence clinics to proprietary, patent‑protected programs seeking regulatory approval. A new narrative review compiles trial outcomes, highlighting modest benefits—primarily brief inflammation reduction—and significant variability across patients and cell batches. The paper also...
FDA Shares New Warning About Johnson & Johnson Heart Pumps After 4 Injuries
The FDA issued an early‑alert notice on February 3, 2026, highlighting a leak risk in Generation 1 purge cassettes used with Johnson & Johnson MedTech’s Impella RP heart‑pump sets. A leak can trigger a low‑pressure alarm, potentially causing biomaterial ingress, pump stoppage, and loss...
Rare Disease Day Insight: Epilepsy Care Gaps in Pregnancy with UCB’s Andrea Wilkinson — Episode 244
The Xtalks Life Science Podcast’s Episode 244 spotlights a persistent gap in epilepsy care for pregnant women, noting that fewer than 5% of clinical trials include this population. Andrea Wilkinson, UCB’s Global Head of Patient Engagement & Advocacy, discusses new...
Baba Emerges From Stealth with $6.5M to Launch Medicare Advocacy Platform
Baba, a patient‑advocacy startup for seniors, announced its emergence from stealth with a $6.5 million seed round led by General Catalyst. The platform blends dedicated nurses and social‑workers with an AI companion to resolve insurance denials, scheduling gaps, and other operational...
![[Comment] Managing Complex Antiretroviral Regimens](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/b8eed98261dfc36d8f4d646ed514fe50.webp)
[Comment] Managing Complex Antiretroviral Regimens
Switching antiretroviral therapy (ART) in people with HIV who have achieved sustained virological suppression is now a routine part of modern care. Advances in drug formulation, tolerability, and the rise of single‑tablet regimens have expanded treatment objectives beyond viral control....
STAT+: A Rare Disease Drug Was Approvable, Then It Wasn’t. Inside a Surprise Rejection by the FDA
An experimental cell therapy for a rare post‑transplant blood cancer, developed by Atara Biotherapeutics and Pierre Fabre, was initially deemed approvable by FDA reviewers but was abruptly rejected in February 2026 over alleged clinical data deficiencies. The disease affects roughly...
Pharmaceutical Executive Daily: FDA Approves Braftovi
The FDA has approved Braftovi for patients with BRAF V600E‑mutant metastatic colorectal cancer, expanding targeted options in a genetically defined subset. The clearance underscores the momentum of biomarker‑driven oncology and combination‑therapy strategies. In parallel, Novo Nordisk announced a $2 billion partnership with Vivtex...
No Pharma Money, Proven Vaccines Safe for Autistic Kids
Haha what an original and inspired conspiracy trope. Search my name in CMS Open Payments. I get $0 from pharma companies. ZERO. ZILCH. I do this because I believe in public health and keeping kids from getting serious illnesses. And because, unlike...
AI Expands Beyond Scribes to Entire Healthcare Practice
The future isn’t just AI scribes — it’s AI across the whole practice. Front desk to billing. Hear Venky Chellappa share @charmhealth's approach at #ViVE2026 👇 https://t.co/Fu8iReWUAZ
How AI Is Transforming Dermatology Care in Austin
Artificial intelligence is now embedded in Austin dermatology clinics, where AI‑driven imaging tools assist physicians in diagnosing skin lesions, classifying conditions, and tracking treatment progress. Studies show deep‑learning models can match dermatologist accuracy for skin‑cancer detection, offering a secondary safety...
Regulatory Pressure Forces Hospitals Back to Fax
When government requirements increase data sharing but systems aren’t connected, the fax machine fills the gap. Jess Czelusniak shares what that reality looked like at VHC Health.👇 Hear more about their experience: https://t.co/D7oXKCb2Kg @VyneMedical @VHCHealth #eFax #HITSM https://t.co/mvrhQyx04R
Oracle Health Sets New Standard for Healthcare Interoperability
The @OracleHealth team isn't waiting for the future of healthcare connectivity—we’re setting the standard: https://t.co/Gw7WFnvODg Through this validation program, we’re building trusted relationships with device vendors, streamlining interoperability, and opening the door for continued collaboration and innovation.
ViVE 2026: Change Management Is Key in Clinical Adoption of AI
At ViVE 2026, Tampa General Hospital highlighted that change management, not technology, is the primary barrier to clinical AI adoption among nurses. The hospital detailed its partnership with Microsoft to deploy an AI assistant that automatically populates custom nursing flow...
FDA Rejects Experimental Rare Blood Cancer Therapy
An experimental therapy for a rare blood cancer was on the path toward approval by the Food and Drug Administration last year — with internal reviewers recommending it be cleared — before the agency rejected the drug last month, @adamfeuerstein...
FDA Rejects Europe‑approved Drug: What Shifted?
Interesting read: the thread and the story. A drug that was approved in Europe in 2022, which looked like it was on track for #FDA approval, instead is rejected. What changed at FDA? 🤔
Q&A: Nemours Children’s Health Expands Pediatric Care at Home
Nemours Children’s Health launched the Advanced Care at Home program, a virtual, technology‑enabled service that lets medically stable pediatric patients recover at home while receiving 24/7 clinical support. The model leverages Epic MyChart and a centralized command center to deliver...
ACIP Meeting Notice Raises Questions on Vaccine Injury Role
The Federal Register notice for the (now) March #ACIP meeting is now up & it's ... puzzling. Possible vote on Covid vaccine injury? ACIP can recommend changes to the way a vaccine is used, for safety reasons. But vaccine injuries aren't...
Dual BCMA‑CD19 Targeting Shows Promise in ASyS
interesting and different efficacy outcomes in ASyS and SSc autoimmune patients treated with blinatumomab (CD3/CD19) and teclistamab (CD3/BCMA), respectively, + Rituximab maintenance. Potential for targeting both BCMA and CD19, especially in ASys. https://t.co/Dyq7h9EeGo
Menopausal Hormone Therapy Does Not Increase Mortality
A Danish register study of over 800,000 women examined the long‑term safety of menopausal hormone therapy (MHT). About 12% of participants used MHT for a median of 1.7 years, and the analysis found no association between MHT use and all‑cause...
Bridging the Translation Gap for Regenerative Tissues
Muvon Therapeutics, a clinical‑stage company developing regenerative muscle treatments, is confronting the translation gap between academic discovery and commercial manufacturing. The firm highlights three core hurdles: co‑developing evolving regulatory frameworks, automating novel manufacturing processes, and recruiting personnel with GMP expertise....
Samsung Joins CEPI Vaccine Network to Prepare for Next Pandemic
Samsung Biologics has joined the Coalition for Epidemic Preparedness Innovations (CEPI) Vaccine Manufacturing Facility Network, committing to develop a ready‑to‑activate recombinant protein vaccine platform. Backed by a $20 million budget, Samsung will pre‑agree manufacturing processes, run simulated outbreak drills, and prepare...
United Unveils Newly Partnered Soft Mist Inhaler; Mannkind Sinks
United Therapeutics announced a partnership to launch a soft‑mist inhaler, targeting more efficient pulmonary drug delivery for its pipeline. The collaboration marks a strategic pivot away from traditional propellant‑based devices and positions United in the growing soft‑mist market. Investors reacted...
Medicines and Healthcare Products Regulatory Agency Confiscates 2,000 Doses of Illegal Weight-Loss Drugs: Report
Britain's Medicines and Healthcare products Regulatory Agency (MHRA) seized nearly 2,000 doses of illegal weight‑loss drugs in raids on sites in Lincolnshire and Nottinghamshire, marking its second major operation in four months. The confiscated products were labelled as containing tirzepatide...
Alkermes’ Richard Pops to Step Down After Three-Decade Run as CEO
Richard Pops will step down as Alkermes CEO on July 31 after a 32‑year tenure, remaining as board chair. COO Blair Jackson will succeed him and join the board during the transition. Under Pops, Alkermes shifted from drug‑delivery to commercial...
Just Two Days of Oatmeal Cut Bad Cholesterol by 10%
A University of Bonn randomized trial published in Nature Communications found that a two‑day, calorie‑restricted diet consisting of 300 g of oatmeal per day reduced LDL cholesterol by about 10 percent in participants with metabolic syndrome. The oat‑rich group also lost roughly...
Music Beats Cancer Aims to Bring Everyone to the Stage
Music Beats Cancer, a nonprofit founded by former cancer researcher Mona Jhaveri, uses live music and a peer‑to‑peer platform to funnel public donations directly to early‑stage biotech firms tackling cancer. By turning song likes into dollars, the organization bridges the...
Stem Cell Therapy Boosts Frailty Walk Test Performance
A randomized trial of a stem cell therapy vs placebo for aging frailty showed durable and dose-dependent improvement in the 6-minute walk test @CellStemCell https://t.co/2jOYuIgUrY https://t.co/04mEV7OdLo
Online Communities Bridge
Online Patient Communities for the E-Patient “Betwixt & Between” a New Pt & an Expert [Aug 29, 2013] @mtmdphd #ASCOConnection https://t.co/IxinXTK715 #mmsm
New Insights Into Hypertension and MACE Reduction in HIV: Steven Grinspoon, MD
A recent analysis of the REPRIEVE randomized trial shows that pitavastatin reduces incident hypertension by 17 % and cuts major adverse cardiovascular events (MACE) by 36 % in adults living with HIV. The findings extend statins’ benefit beyond LDL‑cholesterol lowering, highlighting a...
Identifying Key Barriers to Boost Myeloma Trial Enrollment
Identification of Significant Barriers to Accrual (BtA) to @theNCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to #ClinicalTrials - @mweissmdphd et al. #ASH12 Abstract 3165 https://t.co/i4zO7ktqHJ #mmsm #caxtx #ctsm
Quadruplet Therapy Effective without Early Transplant in NDMM
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD https://t.co/qD26HMx3J8 #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd
60 Million Reasons to Pay Attention: The Investment Thesis Behind Chamber Cardio’s Series A
Chamber Cardio announced a $60 million Series A round in February 2026, led by Frist Cressey Ventures and backed by General Catalyst, Optum Ventures, Healthworx and other investors. The startup offers a two‑sided platform that connects payers with cardiology practices, embedding workflow‑native AI...
Phase 3 Trial Tests Daratumumab Regimens for New AL Amylo
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/uikUnnJd3n
Super Agers Generate More Neurons Than Much Younger Adults
New @Nature The brains of Super Agers produce more neurons than people some 40 years younger, a neurogenesis resilient signature linked to exceptional cognitive health and memory skills https://t.co/tNB0dTea2F
Colo. FD Launches Community Paramedic Program to Curb Repeat 911 Calls
The Grand Junction Fire Department has launched a Community Paramedic Program aimed at curbing repeat 911 calls by providing in‑home follow‑up for high‑utilization patients with chronic illnesses. Designated paramedics will visit residents within 24‑48 hours of an emergency call to...